Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 28, 2023

Real-World Effectiveness of Risankizumab in Patients With Moderate to Severe Psoriasis

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
J Am Acad Dermatol 2023 Sep 20;[EPub Ahead of Print], B Strober, L Ferris, K Callis Duffin, JC Janak, AP Sima, T Eckmann, M Patel, H Photowala, V Garg, A Armstrong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading